A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study th...

Descripción completa

Detalles Bibliográficos
Autores principales: Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Lee, Peter P, Khleif, Samir N, Thurin, Magdalena, Trinchieri, Giorgio, Wang, Ena, Wigginton, Jon, Chaussabel, Damien, Coukos, George, Dhodapkar, Madhav, Håkansson, Leif, Janetzki, Sylvia, Kleen, Thomas O, Kirkwood, John M, Maccalli, Cristina, Maecker, Holden, Maio, Michele, Malyguine, Anatoli, Masucci, Giuseppe, Palucka, A Karolina, Potter, Douglas M, Ribas, Antoni, Rivoltini, Licia, Schendel, Dolores, Seliger, Barbara, Selvan, Senthamil, Slingluff, Craig L, Stroncek, David F, Streicher, Howard, Wu, Xifeng, Zeskind, Benjamin, Zhao, Yingdong, Zocca, Mai-Britt, Zwierzina, Heinz, Marincola, Francesco M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630944/
https://www.ncbi.nlm.nih.gov/pubmed/19105846
http://dx.doi.org/10.1186/1479-5876-6-81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630944/
https://www.ncbi.nlm.nih.gov/pubmed/19105846
http://dx.doi.org/10.1186/1479-5876-6-81

Ejemplares similares